ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0651

Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Abstract Number: 0786

Diagnostic Utility of FibroScan in Screening for Liver Injury in Patients with Inflammatory Arthritis on Treatment with Methotrexate (MTX)
Abstract Number: 0383

Differences Between Male vs. Female Presenting with Back Pain in an Integrated Delivery System
Abstract Number: 0598

Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Abstract Number: 1239

Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
Abstract Number: 1354

Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database
Abstract Number: 0757

Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
Abstract Number: 0102

Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
Abstract Number: 0011

Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Abstract Number: 1872

Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy
Abstract Number: 0166

Digital Extensor Paratenonitis Is Frequent in Early Rheumatoid Arthritis
Abstract Number: 1275

Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
Abstract Number: 0800

Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
Abstract Number: 0170

Direct and Conditional Effects of Epicardial Adipose Tissue Volume on Coronary Plaque Progression in Rheumatoid Arthritis
Abstract Number: 0663

Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].